NCT04064242 - Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

September 19, 2023

Study Completion Date

December 12, 2023

Conditions

Pulmonary Sarcoidosis

Interventions

DRUG

CMK389

single i.v. dose every 4 weeks

DRUG

Placebo

single i.v. dose every 4 weeks

Trial Locations (22)

2900

Novartis Investigative Site, Hellerup

8200

Novartis Investigative Site, Aarhus N

10029

Icahn School Of Med At Mount Sinai ., New York

15213

University of Pittsburgh Medical Center, Pittsburgh

20246

Novartis Investigative Site, Hamburg

21224

John Hopkins Asthma And Alrgy Cntr, Baltimore

27858

East Carolina University ., Greenville

30625

Novartis Investigative Site, Hanover

32610

Univ of Florida College of Medicine x, Gainesville

45147

Novartis Investigative Site, Essen

60596

Novartis Investigative Site, Frankfurt

69126

Novartis Investigative Site, Heidelberg

35294-3300

Novartis Investigative Site, Birmingham

66160-7330

University of Kansas Medical Center, Kansas City

625 00

Novartis Investigative Site, Brno

779 00

Novartis Investigative Site, Olomouc

DK 5000

Novartis Investigative Site, Odense C

15-044

Novartis Investigative Site, Bialystok

90 153

Novartis Investigative Site, Lodz

01-138

Novartis Investigative Site, Warsaw

EH1 1BE

Novartis Investigative Site, Edinburgh

SW3 6PH

Novartis Investigative Site, London